Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Denmark is investing 80 million euro in a quantum computing project intended to bring a commercial-grade system to the Nordic ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

ISLAMABAD: Pakistan can significantly reduce national health expenditure by controlling obesity by creating awareness and ...

Trump's “big, beautiful bill” and frenetic tariff activity have fueled a lobbying gusher in the opening months of his term.

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

Novo Nordisk NVO -1.23% Get Free Report has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.96%. Currently, Novo Nordisk has a ...